Insider Activity Monitoring: GSK plc (GSK)


GSK plc (NYSE:GSK) saw a downside of -1.87% to close Tuesday at $34.70 after subtracting -$0.66 on the day. The 5-day average trading volume is 4,214,300 shares of the company’s common stock. It has gained $35.73 in the past week and touched a new high 2 times within the past 5 days. An average of 3,503,000 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,159,184.

GSK’s 1-month performance is -1.70% or -$0.52 on its low of $34.23 reached on 01/06/23. The company’s shares have touched a 52-week low of $28.47 and high of $47.82, with the stock’s rally to the 52-week high happening on 01/19/23. YTD, GSK has lost -1.25% or -$0.44 and has reached a new high 4 times. However, the current price is down -27.43% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

GSK stock has a beta of 0.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.80 while the price-to-book (PB) in the most recent quarter is 6.25, with the price to cash flow ratio at 13.52.

GSK plc’s quick ratio for the period ended September 29 was 0.70, with the current ratio over the same period at 1.00. As well, the company’s long term debt to equity for the quarter ending September 29 was 2.11, while the total debt to equity was 2.42.. In terms of profitability, the gross margin trailing 12 months is 65.40%. The trailing 12-month EBITDA margin is 28.66% while for the period ending September 29, GSK plc’s operating margin was 17.30%. The firm’s gross profit as reported stood at $30.95 billion against revenue of $46.91 billion.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -31.11% to $4.38 billion, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected GSK to announce $0.96 per share in earnings in its latest quarter, but it posted $1.1, representing a 14.60% surprise. EBITDA for the quarter stood at more than $2.43 billion. GSK stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 60.77 billion, with total debt at $22.12 billion.

Let’s look briefly at GSK plc (GSK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 41.33% to suggest the stock is trending Neutral, with historical volatility in this time period at 15.95%.

The stock’s 5-day moving average is $35.25, reflecting a -2.42% or -$0.86 change from its current price. GSK is currently trading -1.73% above its 20-day SMA, +5.28% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +7.03% and SMA200 by-24.10%.

Stochastic %K and %D was 61.12% and 73.44% and the average true range (ATR) pointed at 0.54. The RSI (14) points at 46.00%, while the 14-day stochastic is at 31.34% with the period’s ATR at 0.57. The stock’s 9-day MACD Oscillator is pointing at -0.08 and 0.10 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for GSK plc (NYSE: GSK), JP Morgan downgraded it to an Underweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for GSK stock have a consensus rating for the stock as Hold. Currently, 2 brokerage advisors rate GSK as a “sell,”, while 12 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.

What is GSK’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $30.19 and a high of $61.88, with their median price target at $38.43. Looking at these predictions, the average price target given by analysts is for GSK plc (GSK) stock is $39.58.


Please enter your comment!
Please enter your name here